ストックスクリーナーアプリを入手
25.24
3.06%
0.75
アフターアワーズ：
25.24
前日終値:
$24.49
開ける：
$24.96
24時間の取引高:
1.17M
Relative Volume:
0.65
時価総額：
$15.50B
収益：
$3.91B
当期純損益:
$823.88M
株価収益率:
19.03
EPS:
1.3262
ネットキャッシュフロー:
$875.28M
1週間 パフォーマンス:
+2.06%
1か月 パフォーマンス:
-3.59%
6か月 パフォーマンス:
-21.86%
1年 パフォーマンス:
+11.53%
1日の値動き範囲:
$24.80
$25.39
1週間の範囲:
$24.45
$25.39
52週間の値動き範囲:
$20.23
$35.43
Genmab Adr Stock (GMAB) Company Profile
Compare GMAB vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GMAB
Genmab Adr
|
25.24 | 15.04B | 3.91B | 823.88M | 875.28M | 1.3262 |
VRTX
Vertex Pharmaceuticals Inc
|
445.04 | 110.59B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.48 | 63.08B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
898.94 | 53.62B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
289.39 | 38.88B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
149.23 | 30.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Genmab Adr Stock (GMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-22 | アップグレード | Goldman | Neutral → Buy |
| 2026-03-27 | 開始されました | Wolfe Research | Outperform |
| 2026-03-02 | 開始されました | Wells Fargo | Overweight |
| 2026-02-17 | 再開されました | Jefferies | Buy |
| 2026-02-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-09-23 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-04-01 | ダウングレード | Bernstein | Mkt Perform → Underperform |
| 2025-03-11 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2025-02-13 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-08 | 開始されました | Redburn Atlantic | Buy |
| 2024-09-04 | 再開されました | Morgan Stanley | Equal-Weight |
| 2024-08-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-07-15 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-02-23 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2024-01-22 | ダウングレード | Citigroup | Neutral → Sell |
| 2023-12-06 | アップグレード | UBS | Neutral → Buy |
| 2023-11-10 | アップグレード | Deutsche Bank | Hold → Buy |
| 2023-11-08 | アップグレード | DNB Markets | Sell → Buy |
| 2023-10-18 | 開始されました | Exane BNP Paribas | Underperform |
| 2023-09-06 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-08-24 | 開始されました | BTIG Research | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2023-05-31 | 開始されました | UBS | Neutral |
| 2023-05-12 | 開始されました | Morgan Stanley | Underweight |
| 2022-12-20 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-11-14 | 開始されました | William Blair | Mkt Perform |
| 2022-11-11 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2022-06-24 | 開始されました | BMO Capital Markets | Market Perform |
| 2022-05-02 | 開始されました | Cowen | Market Perform |
| 2022-03-16 | アップグレード | UBS | Neutral → Buy |
| 2022-01-31 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-12-01 | 開始されました | Berenberg | Sell |
| 2021-09-16 | ダウングレード | Jefferies | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-08-24 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-20 | 開始されました | Deutsche Bank | Buy |
| 2021-01-19 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-09-23 | ダウングレード | Bryan Garnier | Neutral → Sell |
| 2020-09-08 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-06-25 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2020-04-23 | 開始されました | Credit Suisse | Outperform |
| 2020-02-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-01-13 | 開始されました | SunTrust | Buy |
| 2019-12-12 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-09-13 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2019-09-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-08-12 | 開始されました | Guggenheim | Buy |
| 2019-08-12 | 開始されました | Morgan Stanley | Overweight |
| 2019-08-12 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Genmab Adr (GMAB) 最新ニュース
Genmab A/S stock (DK0010272202): Copenhagen shares weaken as investors weigh outlook after updated A - AD HOC NEWS
GMAB Q1 2026 Earnings: EPS Misses Estimates by Over 40% as Stock DeclinesQuarterly Earnings Report - The Legal Advocate
Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons - GlobeNewswire Inc.
Analysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV), Crescent Biopharma (CBIO) and Genmab (GMAB) - The Globe and Mail
GMAB Stock Price, Quote & Chart | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
GMAB vs. ACAD: Which Stock Is the Better Value Option? - MSN
Genmab stock (DK0010272202): Analyst sentiment shifts as earnings forecasts decline - AD HOC NEWS
Genmab Earnings: Strong Patient Uptake and Diverse Late-Stage Pipeline Support Positive Outlook - Morningstar
Oppenheimer Asset Management Inc. Acquires 48,894 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
Pictet Asset Management Holding SA Takes $33.84 Million Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab ADR shows improved relative strength; still shy of benchmark - MSN
BioNTech (BNTX) surges 6.1%: Is this an indication of further gains? - MSN
BioNTech (BNTX) Surges 6.1%: Is This an Indication of Further Gains? - Eastern Progress
Bispecific Antibody Drug Conjugates Market Landscape Report 2026: A $2 Billion Opportunity by 2030 with the 1st Approved BsADC by 2028 - GlobeNewswire Inc.
Bispecific Antibody Market Landscape Report 2026: A Potential $60 Opportunity by 2031Insight on More than 550 Clinical Trials - GlobeNewswire Inc.
Genmab A/S (NASDAQ:GMAB) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Genmab A/S Sponsored ADR $GMAB Shares Bought by Assetmark Inc. - MarketBeat
Corbus Offers Upside Despite Post-FDA Update, Analyst Highlights Competitive Edge - Sahm
827,217 Shares in Genmab A/S Sponsored ADR $GMAB Bought by Perpetual Ltd - marketbeat.com
JPMorgan Chase & Co. Decreases Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Arrowpoint Investment Partners Singapore Pte. Ltd. Takes Position in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab AS (ADR) (US3723032062.SG) Q1 FY2025 earnings call transcript - Yahoo Finance
Terra Nova Asset Management LLC Invests $1.87 Million in Genmab A/S Sponsored ADR $GMAB - MarketBeat
This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
Genmab A/S Touts Strong 2025, Teases Catalyst-Heavy 2026 With Potential 2027 Launches - Yahoo Finance
Alliancebernstein L.P. Has $335.96 Million Stock Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Genmab A/ S: The Biotech Stock Gen Z Is Quietly Watching - AD HOC NEWS
Russell Investments Group Ltd. Has $25.23 Million Holdings in Genmab A/S Sponsored ADR $GMAB - MarketBeat
First Trust Advisors LP Sells 82,922 Shares of Genmab A/S Sponsored ADR $GMAB - MarketBeat
GMAB Earnings History & Surprises | EPS & Revenue Results | GENMAB A/S -SP ADR (NASDAQ:GMAB) - ChartMill
Genmab (GMAB) Upgraded to Strong Buy: Here's Why - MSN
Genmab A/S -SP ADR (NASDAQ:GMAB) Presents a Compelling Value Investment Case - ChartMill
Stocks With Rising Relative Strength: Genmab ADR - Investor's Business Daily
Genmab ADR Shows Improved Relative Strength; Still Shy Of Benchmark - Investor's Business Daily
What is HC Wainwright’s Forecast for Genmab A/S Q1 Earnings? - Defense World
GENMAB A/S -SP ADR (NASDAQ:GMAB) Emerges as a Peter Lynch-Style GARP Investment - ChartMill
Genmab (GMAB) Reports 19% Revenue Growth to $3.7B in 2025 Driven by Proprietary Medicine Sales - Finviz
Genmab A/S (NASDAQ:GMAB) Given New $40.00 Price Target at HC Wainwright - Defense World
Top 3 Health Care stocks That Could Lead To Your Biggest Gains In Q1 - Benzinga
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Genmab A/S (NASDAQ:GMAB) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World
Genmab A/S Q4 Earnings Call Highlights - Yahoo Finance
Genmab A/S (NASDAQ:GMAB) Given Equal Weight Rating at Morgan Stanley - Defense World
Genmab Adr (GMAB) 財務データ
収益
当期純利益
現金流量
EPS
4.65%
1.27%
大文字化:
|
ボリューム (24 時間):